Search

Your search keyword '"van Faassen, Henk"' showing total 197 results

Search Constraints

Start Over You searched for: Author "van Faassen, Henk" Remove constraint Author: "van Faassen, Henk"
197 results on '"van Faassen, Henk"'

Search Results

2. Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

3. Supplementary Figure S4 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

4. Data from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

5. Supplementary Data from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

6. Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models

7. A Novel Antigen Design Strategy to Isolate Single‐Domain Antibodies that Target Human Nav1.7 and Reduce Pain in Animal Models.

10. Discovery and Pre-Clinical Development of a Therapeutically Active Nanobody-based Chimeric Antigen Receptor targeting human CD22

15. Epitope mapping of a blood-brain barrier crossing antibody targeting the cysteine-rich region of IGF1R using hydrogen-exchange mass spectrometry enabled by electrochemical reduction

18. Epitope mapping of a blood–brain barrier crossing antibody targeting the cysteine-rich region of IGF1R using hydrogen-exchange mass spectrometry enabled by electrochemical reduction

26. Development and Characterization of Mouse Monoclonal Antibodies Specific for Clostridiodes (Clostridium) difficile Lipoteichoic Acid

27. Hydrogen-deuterium exchange mass spectrometry reveals three unique binding responses of mAbs directed to the catalytic domain of hCAIX

31. Serum albumin‐binding V H Hs with variable pH sensitivities enable tailored half‐life extension of biologics

32. Development and Characterization of Mouse Monoclonal Antibodies Specific for Clostridiodes (Clostridium) difficile Lipoteichoic Acid

36. Serum albumin‐binding VHHs with variable pH sensitivities enable tailored half‐life extension of biologics.

39. Development and Characterization of Mouse Monoclonal Antibodies Specific for Clostridiodes (Clostridium) difficileLipoteichoic Acid

40. Neutralization of Clostridium difficile toxin B with VHH-Fc fusions targeting the delivery and CROPs domains.

44. Pathogen Proliferation Governs the Magnitude but Compromises the Function of CD8 T Cells1

46. Antibody light chain variable domains and their biophysically improved versions for human immunotherapy

Catalog

Books, media, physical & digital resources